Clarus Wealth Advisors Acquires 161 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Clarus Wealth Advisors raised its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 1.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,383 shares of the financial services provider’s stock after purchasing an additional 161 shares during the period. Clarus Wealth Advisors’ holdings in iShares Biotechnology ETF were worth $1,526,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of IBB. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the third quarter worth $29,000. Highline Wealth Partners LLC bought a new stake in iShares Biotechnology ETF in the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC bought a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth about $36,000. Modus Advisors LLC bought a new stake in iShares Biotechnology ETF in the fourth quarter valued at about $41,000. Finally, Voisard Asset Management Group Inc. acquired a new position in iShares Biotechnology ETF in the third quarter worth about $59,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Down 1.8 %

NASDAQ IBB opened at $131.57 on Wednesday. iShares Biotechnology ETF has a 1-year low of $123.60 and a 1-year high of $150.57. The stock’s 50 day moving average is $137.51 and its two-hundred day moving average is $141.93.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were given a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.